作者
Gennaro Sardella, Frans J Beerkens, George Dangas, Davide Cao, Usman Baber, Samantha Sartori, David J Cohen, Carlo Briguori, Robert Gil, Johny Nicolas, Zhongjie Zhang, Dariusz Dudek, Vijay Kunadian, Ran Kornowski, Giora Weisz, Bimmer Claessen, Steven Marx, Javier Escaned, Kurt Huber, Timothy Collier, David J Moliterno, E Magnus Ohman, Mitchell W Krucoff, Adnan Kastrati, Phillipe Gabriel Steg, Dominick J Angiolillo, Shamir Mehta, Richard Shlofmitz, Samin Sharma, Stuart Pocock, Charles Michael Gibson, Roxana Mehran
发表日期
2022/12
期刊
EuroIntervention
卷号
18
期号
11
页码范围
e897
出版商
Europa Group
简介
Background
Prior coronary artery bypass graft surgery (CABG) patients undergoing percutaneous coronary intervention (PCI) are often older and present with multiple comorbidities. Ticagrelor monotherapy after a short course of dual antiplatelet therapy (DAPT) has emerged as an effective bleeding-avoidance strategy among high-risk patients.
Aims
We aimed to examine the effects of ticagrelor with or without aspirin in prior CABG patients undergoing PCI within the TWILIGHT trial.
Methods
After 3 months of ticagrelor plus aspirin, patients were randomised to either aspirin or placebo, in addition to ticagrelor, for 12 months and compared by prior CABG status. The primary endpoint was Bleeding Academic Research Consortium (BARC) type 2, 3 or 5 bleeding. The key secondary endpoint was all-cause death, myocardial infarction (MI), or stroke.
Results
Out of 7,119 patients, a total of 703 (10.8%) patients had prior …
学术搜索中的文章
G Sardella, FJ Beerkens, G Dangas, D Cao, U Baber… - EuroIntervention, 2022